Polikistik Over Sendromu'nda Gözlenen Biyokimyasal Bozukluklar

Year 2011, Volume: 3 Issue: 1, 42 - 48, 01.04.2011

Ak Yıldırım H

Abstract

Polikistik Over Sendromu reproduktif dönemdeki kadınların %510’unda görülmektedir. Çok sayıda klinik, laboratuar ve deneysel verilere rağmen hala patofizyolojisi hakkında tereddütler vardır. Polikistik steroidogenez bozukluğu, intraovarian faktörler, insülin rezistansı ve hiperinsülinemi, obezite, genetik faktörler, anormal granüloza hücreleri, enzimatik defektler gibi birkaç sistemin bozuk çalışmasının sinerjistik etkisi sonucu ortaya çıkan, multifaktöriyel bir hastalık olarak düşünülebilir. Bu derlemede bu konuların araştırılması amaçlanmıştır

Keywords

Polikistik Over Sendromu, insülin rezistansı

References

• Hart R. Polycystic ovarian syndrome-prognosis and treatment outcomes. Curr Opin Obstet Gynecol. 2007; 19(6): 529-535
• Azziz R, Carmina E, Dewailly D et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006; 91(11): 4237-4245
• Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935; 29: 181-191
• Hassan A, Gordon CM. Polycystic ovary syndrome update in adolescence. Curr Opin Pediatr. 2007; 19(4): 389-397
• Speroff L, Fritz MA. Clinical Gynecologic Endocrinology and Infertility. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005. Chapter 12 Anovulation and the Polycystic Ovary. 465-491
• Harwood K, Vuguin P, DiMartino-Nardi J. Current Approaches to the Diagnosis and Treatment of Polycystic Ovarian Syndrome in Youth. Horm Res. 2007; 68(5): 209–217.
• Taylor AE. Polycystic Ovary Syndrome. Endocrinol Metab Clin North Am. 1998; 27(4): 877-902
• Acien P, Ouereda F, Matallin P et al. Insulin, androgens, and obesity in women with andwithout polycystic ovary syndrome: a heterogeneous group of disorders. Fertil Steril. 1999; 72(1): 32-40
• Barnes R, Rosenfield RL. The Polycystic Ovary Syndrome: Pathogenesis and Treatment. Ann Intern Med. 1989; 110(5): 386-399
• Anttila L, Ding YQ, Ruutiainen K, Erkkola R, Irjala K, Huhtaniemi I. Clinical features and circulating gonadotropin, insulin, and androgen interactions in women with polycystic ovarian disease. Fertil Steril. 1991; 55(6):1057-61.
• Futterweit W. Polycystic Ovary Syndrome: Clinical Perspectives and Management. Obstet Gynaecol Surv. 1999; 54(6): 403-413
• Diamanti-Kandarakisan E, Piperi C. Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. Hum Reprod Update. 2005; 11(6): 631-643.
• Kahsar-Miller MD, Nixon C, Boots LR, Go RC, Azziz R. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril. 2001; 75(1): 53-58
• Chang RJ. Ovarian steroid secretion in PCOS. Seminars Reprod Endocrinol. 1984; 2: 244-246
• Gilling-Smith C, Willis DS, Beard RW, Franks S. Hypersecretion of androstenodione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab. 1994; 79(4): 1158-65
• Polson DW, Wadsworth J, Adams J, Franks S. Polycystic ovaries: a common finding in normal women. Lancet. 1988; 16;1(8590): 870-872.
• Koivunen R, Laatikainen T, Tomas C, Hubtaniemi I, Tapanainen J, Martikainen H. The prevalence of polycystic ovaries in healthy women. Acta Obstet Gynecol Scand. 1999; 78(2): 137-41.
• Pişkinpaşa S, Yıldız BO. Polikistik over sendromu. Hacettepe Tıp Dergisi 2005; 36: 168-174
• Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19: 41-47
• Adams J, Polson D, Frank S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed). 1986; 9;293(6543): 355-359.
• Nobels F, Dewailley D. Puberty and polycystic ovary syndrome: the insulin/Insulin-like growth factor hypothesis. Fertil Steril. 1992; 58(4): 655-66.
• Dokras A, Bochner M, Hollinrake E, Markham S, Vanvoorhis B, Jagasia DH. Screening Women With Polycystic Ovary Syndrome for Metabolic Syndrome Obstet Gynecol. 2005; 106(1): 131-137
• Yildiz BO, Gedik O. Assessment of glucose intolerance and insulin sensitivity in polycystic ovary syndrome. Reprod Biomed Online. 2004; 8(6): 649-656
• Alexander CJ, Tangchitnob EP, Lepor NE. Polycystic Ovary Syndrome: A Major Unrecognized Cardiovascular Risk Factor in Women. Obstet Gynecol. 2009; 2(4): 232-239.
• Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol (Oxf). 1992; 37: 119-125
• Robinson S, Henderson AD, Gelding SV et al. Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol (Oxf). 1996; 44(3): 277-284
• Pirwany IR, Fleming R, Greer IA Packard CJ, Sattar N. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol (Oxf). 2001; 54(4): 447-453.
• Yıldız BO, Haznedaroğlu IC, Kirazli S, Bayraktar M. Global fibrinolytic capacity is decreased inpolycystic ovary syndrome, suggesting a prothrombotic state. J Clin Endocrinol Metab. 2002; 87: 3871-3875
• Andersen P, Seljeflot I, Abdelnoor M et al. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism. 1995; 44(5): 611-616
• Sampson M, Kong C, Patel A, Unwin R, Jacobs HS. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1996; 45: 623-629
• Meade TW, Mellows S, Brozovic M et al. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986; 2(8506): 533-537.
• Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 1995; 332(10): 635–641
• Oral B, Mermi B, Dilek M, Alanoğlu G, Sütçü R. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome. Metabolism. 1997; 46: 454-457
• Erdoğan M, Karadeniz M, Alper GE et al. Thrombin-activatable fibrinolysis inhibitor and cardiovascular risk factors in polycystic ovary syndrome. Exp Clin Endocrinol Diabetes. 2008; 116(3): 143-147
• Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, Blumenfeld Z. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab. 2004; 89(5): 2160-2165
• Nygard O, Vollset SE, Refsum H, Brattstrom L Ueland PM. Total homocystein and cardiovascular disease. J Int Med. 1999; 246(5): 425-454
• Loverro G, Lorusso F, Mei L, Depalo R, Cormio G, Selvaggi L. The plasma homocysteine levels are increased in polycystic ovary syndrome. Gynecol Obstet Invest. 2002; 53(3):157-62.
• Heutling D, Schulz H, Nickel I et al. Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. J Clin Endocrinol Metab. 2008; 93(1): 82-90.
• Çam A, Erdoğan MF. Melatonin. Ankara Üniversitesi Tıp Fakültesi Mecmuası. 2003; 56: 103-112
• Brzezinski A. Melatonin in humans. New Engl J Med. 1997; 336: 186–195.
• Cavallo A. Melatonin and human puberty. Current perspectives. J Pineal Res. 1993; 15: 115–121.
• Luboshitzky R, Shen-Orr Z, Herer P, Nane R. Urinary 6- sulfatoxymelatonin excretion in hyperandrogenic women with polycystic ovary syndrome: the effect of ethynil estradiol - cyproterone acetate treatment. Gynecol Endocrinol. 2003; 17: 441-447